Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID‐19 Spanish inpatients
Crisanto Díez, María Iglesias-González, Maria Giralt‐López, Teresa Rangil, David Sanagustín, Mónica Moreira, Maite López‐Ramentol, Ana Ibáñez‐Caparrós, Maria‐Eulalia Lorán, Tatiana Bustos‐Cardona, Inés Menéndez‐Cuiñas, P. Mundo-Cid, Laura Blanco, Joan de Pablo, Jorge Cuevas‐Esteban
Abstract
OBJECTIVE: To determine how mental disorders and psychopharmacological treatments before and during COVID-19 hospital admissions are related to mortality. METHODS: Subjects included in the study were all adult patients with a diagnosis of COVID-19, confirmed clinically and by PCR, who were admitted to a tertiary university hospital in Badalona (Spain) between March 1 and November 17, 2020. Data were extracted anonymously from computerized clinical records. RESULTS: 2,150 subjects were included, 57% males, mean age 61 years. History of mental disorders was registered in 957 (45%). Throughout admission, de novo diagnosis of mood or anxiety, stress, or adjustment disorder was made in 12% of patients without previous history. Delirium was diagnosed in 10% of cases. 1011 patients (47%) received a psychotropic prescription during admission (36% benzodiazepines, 22% antidepressants, and 21% antipsychotics). Mortality rate was 17%. Delirium during admission and history of mood disorder were independently associated with higher mortality risk (hazard ratios, 1.39 and 1.52 respectively), while previous year's treatments with anxiolytics/hypnotics and antidepressants were independently associated with lower mortality risk (hazard ratios, 0.47 and 0.43, respectively). CONCLUSION: Mental symptoms are very common in patients hospitalized for COVID-19 infection. Detecting, diagnosing, and treating them is key to determining the prognosis of the disease and functional recovery.